5 Things to Know About Zypitamag |
Learn why prescribers are switching their patients to Zypitamag! |
Understanding the FDA Approval Pathway for Zypitamag (pitavastatin) tablets |
Understanding Zypitamag (pitavastatin) tablets and Myalgia |
Zypitamag (pitavastatin) tablets has Reduced Potential for Certain Drug-Drug Interactions |
A Conversation about ZypitamagPresenter: Dr. Elena Christofides |
Optimizing Statin Treatment with ZypitamagPresenter: Dr. Eliot A. Brinton |
A New Pitavastatin Option for Lipid ManagementPresenter: Dr. Matthew Budoff |
Utilizing Zypitamag (pitavastatin) tablets within the 2018 Guidelines for the Management of Blood CholesterolPresenter: Dr. Gregory Pokrywka |
INDICATIONS & USAGE
ZYPITAMAG is indicated as an adjunctive therapy to diet in adult patients with primary hyperlipidemia or mixed dyslipidemia to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C). Limitations of Use: The effect of ZYPITAMAG on cardiovascular morbidity and mortality has not been determined.
CONTRAINDICATIONS: ZYPITAMAG is contraindicated in patients with a known hypersensitivity to product components, in patients with active liver disease (which may include unexplained persistent elevations in hepatic transaminase levels), in women who are pregnant or may become pregnant, in nursing mothers, or in co-administration with cyclosporine.
WARNINGS & PRECAUTIONS
ADVERSE REACTIONS: The most frequent adverse reactions (rate ≥ 2%) are myalgia, back pain, diarrhea, constipation and pain in extremity. This is not a complete list of all reported adverse events.
For additional information, refer to full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.